{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:39:57Z","timestamp":1792777197320,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA290173-01"],"award-info":[{"award-number":["1R01CA290173-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA237235-01A1"],"award-info":[{"award-number":["1R01CA237235-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA198138"],"award-info":[{"award-number":["1R01CA198138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA290173-01"],"award-info":[{"award-number":["1R01CA290173-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA237235-01A1"],"award-info":[{"award-number":["1R01CA237235-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["1R01ES030948-01"],"award-info":[{"award-number":["1R01ES030948-01"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["C-1792"],"award-info":[{"award-number":["C-1792"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    BAP1 and HMGB1 alterations are implicated in the pathogenesis of mesothelioma, an aggressive cancer of the membranes covering the thoracic and abdominal cavities. Genetic inactivating mutations of\n                    <jats:italic>BAP1<\/jats:italic>\n                    cause cancer in ~100% of carriers. The mechanism\/s that regulate BAP1 expression were unknown. We discovered that HMGB1 directly modulates BAP1 expression. Studying our\n                    <jats:italic>Hmgb1<\/jats:italic>\n                    knock-out mouse mesothelioma models, primary fibroblasts obtained from carriers of pathogenic heterozygous germline\n                    <jats:italic>BAP1<\/jats:italic>\n                    mutations, and mesothelioma cell lines, we discovered that HMGB1 loss caused a significant reduction in\n                    <jats:italic>BAP1<\/jats:italic>\n                    expression and protein levels, whereas HMGB1 overexpression increased\n                    <jats:italic>BAP1<\/jats:italic>\n                    mRNA and protein levels. We demonstrated that HMGB1 binds to the\n                    <jats:italic>BAP1<\/jats:italic>\n                    promoter and activates its transcription, leading to BAP1 overexpression, which in turn promoted the proliferation, migration, and invasion of mesothelioma cells. These findings were confirmed in lung, colon, and cholangiocarcinoma cell lines. These findings indicate that while\n                    <jats:italic>BAP1<\/jats:italic>\n                    inactivating mutations promote cancer development, cancer cells that do not express BAP1 are less aggressive, pointing to the HMGB1-BAP1 axis as a novel attractive target for therapy. Furthermore, our discovery that HMGB1-driven BAP1 overexpression supports cancer growth provides a mechanistic rationale for the improved survival observed in mesothelioma patients with somatic\n                    <jats:italic>BAP1<\/jats:italic>\n                    inactivating mutations.\n                  <\/jats:p>","DOI":"10.1038\/s41418-026-01892-6","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:17:02Z","timestamp":1792775822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HMGB1 directly activates BAP1 transcription to sustain tumor growth in mesothelioma"],"prefix":"10.1038","author":[{"given":"Flavia","family":"Novelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Giannakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9908-4317","authenticated-orcid":false,"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Favaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Maldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1528-2701","authenticated-orcid":false,"given":"Joelle S.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia A.","family":"Zolondick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bononi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"MacPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euisung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-8213","authenticated-orcid":false,"given":"Youping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6766-861X","authenticated-orcid":false,"given":"Tak W.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose N.","family":"Onuchic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-8474","authenticated-orcid":false,"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-2420","authenticated-orcid":false,"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1892_CR1","first-page":"402","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR, Baas P Jr, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329.","journal-title":"CA Cancer J Clin"},{"key":"1892_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21037\/atm.2017.04.29","volume":"5","author":"M Carbone","year":"2017","unstructured":"Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017;5:238.","journal-title":"Ann Transl Med"},{"key":"1892_CR3","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA. 2010;107:12611\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1892_CR4","doi-asserted-by":"crossref","unstructured":"Xue J, Patergnani S, Giorgi C, Suarez JS, Goto K, Bononi A, et al. Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proc Natl Acad Sci USA. 2020;117:25543\u201352.","DOI":"10.1073\/pnas.2007622117"},{"key":"1892_CR5","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","volume":"72","author":"S Jube","year":"2012","unstructured":"Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72:3290\u2013301.","journal-title":"Cancer Res"},{"key":"1892_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep22850","volume":"6","author":"R Mezzapelle","year":"2016","unstructured":"Mezzapelle R, Rrapaj E, Gatti E, Ceriotti C, Marchis FD, Preti A, et al. Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells. Sci Rep. 2016;6:22850.","journal-title":"Sci Rep"},{"key":"1892_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41747-021-00260-y","volume":"6","author":"M Venturini","year":"2022","unstructured":"Venturini M, Mezzapelle R, La Marca S, Perani L, Spinelli A, Crippa L, et al. Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study. Eur Radio Exp. 2022;6:7.","journal-title":"Eur Radio Exp"},{"key":"1892_CR8","doi-asserted-by":"publisher","first-page":"22649","DOI":"10.18632\/oncotarget.15152","volume":"8","author":"L Pellegrini","year":"2017","unstructured":"Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, et al. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget. 2017;8:22649\u201361.","journal-title":"Oncotarget"},{"key":"1892_CR9","doi-asserted-by":"publisher","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","volume":"6","author":"H Yang","year":"2015","unstructured":"Yang H, Pellegrini L, Napolitano A, Giorgi C, Jube S, Preti A, et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis. 2015;6:e1786.","journal-title":"Cell Death Dis"},{"key":"1892_CR10","doi-asserted-by":"crossref","unstructured":"Carbone M, Harbour WJ, Brugarolas J, Bononi A, Pagano I, Dey A, et al. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 2020;10:1103\u201320.","DOI":"10.1158\/2159-8290.CD-19-1220"},{"key":"1892_CR11","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1016\/j.molcel.2021.06.020","volume":"81","author":"E Conway","year":"2021","unstructured":"Conway E, Rossi F, Fernandez-Perez D, Ponzo E, Ferrari KJ, Zanotti M, et al. BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation. Mol cell. 2021;81:3526\u201341.e3528.","journal-title":"Mol cell"},{"key":"1892_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41418-020-00709-4","volume":"28","author":"L Masclef","year":"2021","unstructured":"Masclef L, Ahmed O, Estavoyer B, Larrivee B, Labrecque N, Nijnik A, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ. 2021;28:606\u201325.","journal-title":"Cell Death Differ"},{"key":"1892_CR13","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/cdd.2017.95","volume":"24","author":"A Bononi","year":"2017","unstructured":"Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ. 2017;24:1694\u2013704.","journal-title":"Cell Death Differ"},{"key":"1892_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","volume":"546","author":"A Bononi","year":"2017","unstructured":"Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature. 2017;546:549\u201353.","journal-title":"Nature"},{"key":"1892_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6128","volume":"5","author":"HS Lee","year":"2014","unstructured":"Lee HS, Lee SA, Hur SK, Seo JW, Kwon J. Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis. Nat Commun. 2014;5:5128.","journal-title":"Nat Commun"},{"key":"1892_CR16","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","volume":"74","author":"IH Ismail","year":"2014","unstructured":"Ismail IH, Davidson R, Gagne JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 2014;74:4282\u201394.","journal-title":"Cancer Res"},{"key":"1892_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.1309085110","volume":"111","author":"H Yu","year":"2014","unstructured":"Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA. 2014;111:285\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1892_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1126\/science.aav4902","volume":"364","author":"M He","year":"2019","unstructured":"He M, Chaurushiya MS, Webster JD, Kummerfeld S, Reja R, Chaudhuri S, et al. Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1. Science. 2019;364:283\u20135.","journal-title":"Science"},{"key":"1892_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax1738","volume":"5","author":"JN Kuznetsov","year":"2019","unstructured":"Kuznetsov JN, Aguero TH, Owens DA, Kurtenbach S, Field MG, Durante MA, et al. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019;5:eaax1738.","journal-title":"Sci Adv"},{"key":"1892_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06854-2","volume":"9","author":"S Daou","year":"2018","unstructured":"Daou S, Barbour H, Ahmed O, Masclef L, Baril C, Sen Nkwe N, et al. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1. Nat Commun. 2018;9:4385.","journal-title":"Nat Commun"},{"key":"1892_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181\u201392.","journal-title":"Nat Cell Biol"},{"key":"1892_CR22","doi-asserted-by":"crossref","unstructured":"Carbone M, Minaai M, Kittaneh M, Krausz T, Miettinen MM, Pan Hammarstrom Q, et al. Clinical and pathologic phenotyping of mesotheliomas developing in carriers of germline BAP1 mutations. J Thorac Oncol. 2025;20:1683\u201398.","DOI":"10.1016\/j.jtho.2025.06.020"},{"key":"1892_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-179","volume":"10","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179.","journal-title":"J Transl Med"},{"key":"1892_CR24","doi-asserted-by":"crossref","unstructured":"Carbone M, Pass HI, Ak G, Alexander HR, Jr, Baas P, et al. Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations. J Thorac Oncol. 2022;17:873\u201389.","DOI":"10.1016\/j.jtho.2022.03.014"},{"key":"1892_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1559-7","volume":"16","author":"M Kittaneh","year":"2018","unstructured":"Kittaneh M, Berkelhammer C. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. J Transl Med. 2018;16:194.","journal-title":"J Transl Med"},{"key":"1892_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.canlet.2016.05.011","volume":"378","author":"M Betti","year":"2016","unstructured":"Betti M, Aspesi A, Biasi A, Casalone E, Ferrante D, Ogliara P, et al. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett. 2016;378:120\u201330.","journal-title":"Cancer Lett"},{"key":"1892_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/carcin\/bgu227","volume":"36","author":"F Baumann","year":"2015","unstructured":"Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36:76\u201381.","journal-title":"Carcinogenesis"},{"key":"1892_CR28","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","volume":"36","author":"S Pastorino","year":"2018","unstructured":"Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36:3485\u201394. JCO2018790352).","journal-title":"J Clin Oncol"},{"key":"1892_CR29","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","volume":"116","author":"R Hassan","year":"2019","unstructured":"Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019;116:9008\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1892_CR30","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36:2863\u201371.","journal-title":"J Clin Oncol"},{"key":"1892_CR31","doi-asserted-by":"crossref","unstructured":"Wu X, Hernandez FV, Wang H, Wang R, Shiffka S, Shah N, et al. Prospective analysis of mesotheliomas in subjects with BAP1 cancer syndrome: clinical characteristics and epigenetic correlates of disease. J Thorac Oncol. 2025;20:1699\u2013715.","DOI":"10.1016\/j.jtho.2025.07.132"},{"key":"1892_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/1078-0432.CCR-23-2431","volume":"30","author":"F Passiglia","year":"2024","unstructured":"Passiglia F, Righi L, Bironzo P, Listi A, Farinea G, Capelletto E, et al. Niraparib plus dostarlimab in pleural mesothelioma or non-small cell lung cancer harboring HRR mutations: interim results of the UNITO-001 phase II prospective trial. Clin Cancer Res. 2024;30:959\u201364.","journal-title":"Clin Cancer Res"},{"key":"1892_CR33","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jtho.2025.09.007","volume":"20","author":"F Galateau-Salle","year":"2025","unstructured":"Galateau-Salle F. Mesothelioma in BAP1 cancer syndrome and contribution of epigenetic. J Thorac Oncol. 2025;20:1580\u20131.","journal-title":"J Thorac Oncol"},{"key":"1892_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jtho.2025.08.003","volume":"20","author":"A Ghafoor","year":"2025","unstructured":"Ghafoor A, Perez CO, Hassan R. Germline BAP1 mutation-associated mesothelioma: a biologically and clinically distinct entity. J Thorac Oncol. 2025;20:1577\u20139.","journal-title":"J Thorac Oncol"},{"key":"1892_CR35","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10:565\u201376.","journal-title":"J Thorac Oncol"},{"key":"1892_CR36","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","volume":"113","author":"Y Yoshikawa","year":"2016","unstructured":"Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci USA. 2016;113:13432\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1892_CR37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","volume":"17","author":"A Louw","year":"2022","unstructured":"Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, et al. BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study. J Thorac Oncol. 2022;17:921\u201330.","journal-title":"J Thorac Oncol"},{"key":"1892_CR38","doi-asserted-by":"crossref","unstructured":"Novelli F, Bononi A, Wang Q, Bai F, Patergnani S, Kricek F, et al. BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene x environment interaction with asbestos. Proc Natl Acad Sci USA. 2021;118:e2111946118.","DOI":"10.1073\/pnas.2111946118"},{"key":"1892_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307999120","volume":"120","author":"JS Suarez","year":"2023","unstructured":"Suarez JS, Novelli F, Goto K, Ehara M, Steele M, Kim JH, et al. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma. Proc Natl Acad Sci USA. 2023;120:e2307999120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1892_CR40","doi-asserted-by":"crossref","unstructured":"Watson M. Mapping intramolecular interactions between domains in HMGB1 using a tail-truncation approach. J Mol Biol. 2007;374:1286\u201397.","DOI":"10.1016\/j.jmb.2007.09.075"},{"key":"1892_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-024-10204-6","volume":"25","author":"M Liao","year":"2024","unstructured":"Liao M, Cao J, Chen W, Wang M, Jin Z, Ye J, et al. HMGB1 prefers to interact with structural RNAs and regulates rRNA methylation modification and translation in HeLa cells. BMC Genomics. 2024;25:345.","journal-title":"BMC Genomics"},{"key":"1892_CR42","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41417-025-00963-z","volume":"32","author":"L Ma","year":"2025","unstructured":"Ma L, Xu M, Xu S, Guo X, Zong W, Zhao X, et al. HMGB1 downregulates DDX3 to activate the MAPK pathway, promoting the progression of colorectal cancer. Cancer Gene Ther. 2025;32:1307\u201318.","journal-title":"Cancer Gene Ther"},{"key":"1892_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-165","volume":"13","author":"B Pan","year":"2014","unstructured":"Pan B, Chen D, Huang J, Wang R, Feng B, Song H, et al. HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Mol Cancer. 2014;13:165.","journal-title":"Mol Cancer"},{"key":"1892_CR44","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41388-018-0485-8","volume":"38","author":"YF Xu","year":"2019","unstructured":"Xu YF, Liu ZL, Pan C, Yang XQ, Ning SL, Liu HD, et al. HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium. Oncogene. 2019;38:868\u201380.","journal-title":"Oncogene"},{"key":"1892_CR45","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.18632\/oncotarget.2201","volume":"5","author":"Q Li","year":"2014","unstructured":"Li Q, Li J, Wen T, Zeng W, Peng C, Yan S, et al. Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1\/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. Oncotarget. 2014;5:6387\u2013403.","journal-title":"Oncotarget"},{"key":"1892_CR46","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1158\/1078-0432.CCR-14-3379","volume":"22","author":"M Rao","year":"2016","unstructured":"Rao M, Atay SM, Shukla V, Hong Y, Upham T, Ripley RT, et al. Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells. Clin Cancer Res. 2016;22:1197\u2013210.","journal-title":"Clin Cancer Res"},{"key":"1892_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29017-w","volume":"13","author":"M Kang","year":"2023","unstructured":"Kang M, Park SG, Lee SA, Kim S, Lee D, Shirbhate ME, et al. Targeting BAP1 with small compound inhibitor for colon cancer treatment. Sci Rep. 2023;13:2264.","journal-title":"Sci Rep"},{"key":"1892_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9471","volume":"6","author":"J Qin","year":"2015","unstructured":"Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge G, et al. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nat Commun. 2015;6:8471.","journal-title":"Nat Commun"},{"key":"1892_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05085-9","volume":"9","author":"S Asada","year":"2018","unstructured":"Asada S, Goyama S, Inoue D, Shikata S, Takeda R, Fukushima T, et al. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun. 2018;9:2733.","journal-title":"Nat Commun"},{"key":"1892_CR50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.7150\/jca.65574","volume":"13","author":"YC Yan","year":"2022","unstructured":"Yan YC, Meng GX, Ding ZN, Liu YF, Chen ZQ, Yan LJ, et al. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies. J Cancer. 2022;13:88\u2013101.","journal-title":"J Cancer"},{"key":"1892_CR51","doi-asserted-by":"crossref","unstructured":"Liu-Smith F. Opposite roles of BAP1 in overall survival of uveal melanoma and cutaneous melanoma. J Clin Med. 2020;9:411.","DOI":"10.3390\/jcm9020411"},{"key":"1892_CR52","doi-asserted-by":"crossref","unstructured":"Liu X. BAP1 is a novel target in HPV-negative head and neck cancer. Clin Cancer Res. 2018;24:600\u20137.","DOI":"10.1158\/1078-0432.CCR-17-1573"},{"key":"1892_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bbagrm.2009.11.014","volume":"1799","author":"D Tang","year":"2010","unstructured":"Tang D, Kang R, Zeh HJ, Lotze MT 3rd. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799:131\u201340.","journal-title":"Biochim Biophys Acta"},{"key":"1892_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75783-2","volume":"10","author":"CQ Wang","year":"2020","unstructured":"Wang CQ, Huang BF, Wang Y, Tang CH, Jin HC, Shao F, et al. Subcellular localization of HMGB1 in colorectal cancer impacts on tumor grade and survival prognosis. Sci Rep. 2020;10:18587.","journal-title":"Sci Rep"},{"key":"1892_CR55","first-page":"6799","volume":"15","author":"L Wu","year":"2018","unstructured":"Wu L, Yang L. The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications. Oncol Lett. 2018;15:6799\u2013805.","journal-title":"Oncol Lett"},{"key":"1892_CR56","doi-asserted-by":"publisher","first-page":"368504251362343","DOI":"10.1177\/00368504251362343","volume":"108","author":"A Jiraviriyakul","year":"2025","unstructured":"Jiraviriyakul A, Promchai S, Nensat C, Khutanthong S, Singpan N, Songjang W. Higher expression of high-mobility group box 1 in cholangiocarcinoma and association with cell growth, in vitro migration and invasion, and chemo-drug sensitivity. Sci Prog. 2025;108:368504251362343.","journal-title":"Sci Prog"},{"key":"1892_CR57","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1038\/s41586-024-08416-7","volume":"636","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Addendum: accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;636:E4.","journal-title":"Nature"},{"key":"1892_CR58","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696\u2013713.","journal-title":"J Chem Theory Comput"},{"key":"1892_CR59","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1021\/acs.jctc.5b00716","volume":"11","author":"M Zgarbova","year":"2015","unstructured":"Zgarbova M, Sponer J, Otyepka M, Cheatham TE, Galindo-Murillo R 3rd, et al. Refinement of the sugar-phosphate backbone torsion beta for AMBER force fields improves the description of Z- and B-DNA. J Chem Theory Comput. 2015;11:5723\u201336.","journal-title":"J Chem Theory Comput"},{"key":"1892_CR60","doi-asserted-by":"publisher","DOI":"10.1063\/1.4872239","volume":"140","author":"MF Harrach","year":"2014","unstructured":"Harrach MF, Drossel B. Structure and dynamics of TIP3P, TIP4P, and TIP5P water near smooth and atomistic walls of different hydroaffinity. J Chem Phys. 2014;140:174501.","journal-title":"J Chem Phys"},{"key":"1892_CR61","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.1021\/acs.jctc.6b00701","volume":"12","author":"H Wang","year":"2016","unstructured":"Wang H, Gao X, Fang J. Multiple staggered mesh Ewald: boosting the accuracy of the smooth particle mesh Ewald method. J Chem Theory Comput. 2016;12:5596\u2013608.","journal-title":"J Chem Theory Comput"},{"key":"1892_CR62","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","volume":"52","author":"MRA Parrinello","year":"1981","unstructured":"Parrinello MRA. Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys. 1981;52:7182\u201390.","journal-title":"J Appl Phys"},{"key":"1892_CR63","doi-asserted-by":"crossref","unstructured":"Bussi GDD, Parrinello M. Canonical sampling through velocity rescaling. J Chem Phys. 2007;126:014101.","DOI":"10.1063\/1.2408420"},{"key":"1892_CR64","doi-asserted-by":"crossref","unstructured":"Van Der Spoel DL E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26:1701\u201318.","DOI":"10.1002\/jcc.20291"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01892-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01892-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01892-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:17:05Z","timestamp":1792775825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01892-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":64,"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01892-6","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MC and HY have a patent issued for \u201cUsing Anti-HMGB1 Monoclonal Antibody or other HMGB1 Antibodies as a Novel Mesothelioma Therapeutic Strategy,\u201d and a patent issued for \u201cHMGB1 As a Biomarker for Asbestos Exposure and Mesothelioma Early Detection\u201d. MC is a board-certified pathologist and provides consultation for pleural pathology, including medical-legal.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal care and experiments were in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines (\n                      \n                      ) and with approval from the University of Hawaii Institutional Animal Care and Use Committee (Protocol # 09-682).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All the authors are aware of and agree to the content of the paper and their being listed as a co-author of the paper.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}